Ahmedabad, India-headquartered Intas Pharmaceuticals Ltd., signed an exclusive global licensing deal with Syna Therapeutics, a joint venture of Reig Jofre and Leanbio headquartered at Barcelona Science Park, Spain.
Syna will develop and manufacture LB-0702 that is used to treat pathologies in the field of hematology, Intas will commercialize this biosimilar drug through its worldwide affiliates. Accord Healthcare, Intas’ wholly-owned subsidiary, has one of the largest sales and distribution networks in 85 countries globally.
Leanbio’s technology platforms will be used to develop and manufacture the biosimilar, along with Reig Jofre’s technology production expertise at its new manufacturing plant in Barcelona which specializes in sterile injectables and freeze-dried biopharmaceuticals.
Dr Andreu Soldevila, co-founder and CEO of Syna said, “We are delighted with this agreement with Intas because we believe biosimilar LB-0702 will have a very positive impact on healthcare systems. With this collaboration, we are committed to further strengthening the value of our biosimilar programs in global markets.”
